Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 12 weeks as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12) To evaluate the safety and tolerability of treatment with SOF/VEL/GS-9857
Critère d'inclusion
- Chronic hepatitis C virus infection